Eli Lilly’s $1 Billion India Investment Fuels Global Expansion and Manufacturing Strategy
Eli Lilly & Co. shares climbed 1.57% to $853.05 following its announcement of a $1 billion investment in Indian pharmaceutical manufacturing. The MOVE accelerates the company's global supply chain strategy, with Hyderabad slated to become a production hub for diabetes and obesity treatments.
The India commitment follows Lilly's $5 billion Virginia facility plan, part of a broader $27 billion capacity expansion. Local recruitment has already begun for contract manufacturing operations, positioning India as a critical node in Lilly's international infrastructure network.